• info@arocell.com
  • +46 (0)18 50 30 20
  • English
  • Svenska
Arocell TK 210 ELISA
  • about
    • A word from the CEO
    • Vision and mission
    • Strategy and goals
    • Board of Directors
    • Management
    • Partnership
    • Company history
    • Policies
  • product
    • AroCell TK 210 ELISA
    • Why measure Thymidine Kinase 1?
    • Performance and technical specifications
    • Instructions for use
  • applications
    • Drug discovery and development
    • Clinical cancer research
    • Clinical studies
    • Scientific references
    • Posters and presentations
  • technologies
    • Thymidine Kinase 1
    • Patent portfolio
    • Scientific references
    • Posters and presentations
  • news & media
    • News
    • Press releases
    • Events
  • investors
    • AroCell – Company overview
    • The share
    • Financial report
    • Mergers & Acquisitions
    • Analyst coverage
    • Share issues
    • Press releases
    • Financial presentations
    • Financial calendar
    • General Meeting
    • Annual General Meeting
    • Governance
    • Certified advisor
    • Investor relations contact
  • contact & order
    • Contact
    • Distributors
    • Service
    • Order
    • Q & A
Menu
  • about
    • A word from the CEO
    • Vision and mission
    • Strategy and goals
    • Board of Directors
    • Management
    • Partnership
    • Company history
    • Policies
  • product
    • AroCell TK 210 ELISA
    • Why measure Thymidine Kinase 1?
    • Performance and technical specifications
    • Instructions for use
  • applications
    • Drug discovery and development
    • Clinical cancer research
      • Hematological malignancies
      • Breast cancer
      • Other solid tumors
    • Clinical studies
    • Scientific references
    • Posters and presentations
  • technologies
    • Thymidine Kinase 1
    • Patent portfolio
    • Scientific references
    • Posters and presentations
  • news & media
    • News
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
    • Press releases
    • Events
  • investors
    • AroCell – Company overview
    • The share
      • Ownership structure
      • Insider trading
    • Financial report
    • Mergers & Acquisitions
    • Analyst coverage
    • Share issues
      • New share issue 2022
      • NEW SHARE ISSUE 2021
      • New share issue 2019
      • Nyemission 2018
      • Listing at First North 2016
      • Nyemission 2015
    • Press releases
    • Financial presentations
    • Financial calendar
    • General Meeting
      • Extraordinary General Meeting 2022
      • Extraordinary General Meeting 2021
    • Annual General Meeting
      • Annual General Meeting 2022
      • Annual General Meeting 2021
      • Annual General Meeting 2020
      • Annual General Meeting 2019
      • Annual General Meeting 2018
      • Annual general meeting 2017
      • Annual general meeting 2016
      • Annual general meeting 2015
    • Governance
      • Board of Directors
      • Management
      • Articles of association
      • Nomination committee
    • Certified advisor
    • Investor relations contact
  • contact & order
    • Contact
    • Distributors
    • Service
    • Order
    • Q & A

Categories

  • News
  • Press Releases
    • Corporate Action
      • M&A
      • Other
      • Prospectus
      • Shares
        • Issuance
    • Corporate Information
      • General meeting
        • Notice
        • Raport bolagsstämman
      • Nomination Committee
      • Staff change
    • Correction
    • English
    • IR
    • PR
    • Regulatory
      • Listing Regulation
      • MAR
    • Report
      • Annual
      • Interim
        • Q1
        • Q2
        • Q3
        • Yearend

Report from the Annual General Meeting of AroCell

19 May 2016

Report from the Annual General Meeting of AroCell  English

Kommuniké från årsstämman i AroCell  Swedish

Latest posts

  • IDL Biotech AB publishes interim report April 1st to June 30th 2021

    22 July 2021
  • Get to know Jonas Söderholm!

    12 April 2021
  • CEO, Anders Hultman, Commenting on FDA delay due to Covid-19

    20 January 2021
  • Commenting CEO Transition, interview by Redeye

    12 January 2021
  • We wish you a Merry Christmas!

    21 December 2020

Archive

  • 2021
    • IDL Biotech AB publishes interim report April 1st to June 30th 2021

    • Get to know Jonas Söderholm!

    • CEO, Anders Hultman, Commenting on FDA delay due to Covid-19

    • Commenting CEO Transition, interview by Redeye

  • 2020
    • We wish you a Merry Christmas!

    • AroCell TK 210 ELISA can now be used on automated platforms

    • Redeye interview with Michael Brobjer

    • New research note on AroCells previous analysis from Redeye

    • AroCell Strategy day 2020

    • New article in DI

    • AACR 2020: New data on AroCell TK 210 ELISA now online

    • Redeye adds a new research note to AroCells previous analysis

    • Monitoring CDK 4/6 Inhibitors in Breast Cancer

    • New Article in DI Life Science

  • 2019
    • Christmas letter 2019

    • Presented Poster at ESMO Asia Congress 2019

    • Michael Brobjer, CEO, presents the quarterly report plus Q&A with Redeye

    • Video interview with CEO Michael Brobjer and CFO Anders Hultman from Redeye

    • Today’s lunch seminar presentation at Uppsala Business Park

    • New video interview with Michael Brobjer by Redeye

    • Thymidine Kinase 1 can be used for early detection of therapy response in breast cancer treatment

    • AroCell expands with a Regulatory Affairs Director

    • Redeye adds a new research note to AroCells analysis

    • Redeye interviewing AroCell’s CEO, Michael Brobjer (video)

    • AroCell AB (publ) Interim Report January 1st to June 30th 2019

    • AroCell signs a new distributor agreement in the USA and Canada

    • AroCell enters a collaboration with Dana Farber Cancer Institute

    • Redeye published an analysis of AroCell AB

    • AroCell in Swedish magazine Dagens Industri – DI Almedalen

    • Thymidine Kinase 1 (TK1) as a biomarker for therapy response in treatment of breast cancer patients

    • AroCell TK 210 ELISA can be shipped at ambient temperature within Europe

    • Comparison between the AroCell TK 210 ELISA and TK1 enzyme activity assays

    • AroCell AB (publ) Interim Report 1st January to 31st March 2019

    • AroCell expands its distribution network and signs distribution agreement with Inveniolife

    • Swedish National Board of Health and Welfare’s report present the cancer development of the future in Sweden – AroCell, a potential player

    • NOTICE OF ANNUAL GENERAL MEETING OF AROCELL AB (PUBL)

    • AroCell establish a Scientific Advisory Board

    • AroCell and Corgenix establish the measurement of Thymidine Kinase 1 using AroCell TK 210 ELISA in a CLIA-lab in the USA

    • AroCell’s 2018 Annual Report published

    • New AroCell patent granted by the EPO

    • CORRECTED VERSION of March 20, 2019 Press Release: New scientific publication from AroCell on TK 210 ELISA in prostate cancer

    • New scientific publication from AroCell on TK 210 ELISA in prostate cancer

    • Abstract from AroCell accepted for poster presentation during AACR 2019

    • New study results with AroCell TK 210 ELISA in prostate cancer has been accepted for publication

    • Year end report 2018

    • AroCell in a Swedish business magazine Affärsvärlden no.7 2019

    • AroCell’s CEO share his views on the company in a video interview

    • AroCell visiting Future Diagnostic in the Netherlands

    • AroCell launches new website

    • AroCell is a member of SwedenBIO

    • AroCell signs distribution agreement with Gongyingshi in China for AroCell TK 210 ELISA

  • 2018
    • AroCell signs distribution agreement with Eurobio Scientific in France

    • A new scientific publication from AroCell confirming the value of AroCell TK 210 ELISA as a tool in drug discovery and development

    • AroCell presents results from the U-CAN TK1 lymphoma study and from a comparison study between TK 210™ ELISA and other assays

    • November Newsletter 2018

    • Interim Report Q3 2018

    • AroCell AB announces the appointment of a new CEO

    • Patent granted in the US

    • A second abstract accepted at ISOBM in Hamburg demonstrating enhanced diagnostic value when using AroCell’s proprietary sample preparation method

    • September Newsletter 2018

    • TK 210 ELISA compared to other methods

    • Interim Report Q2 2018

    • Patent reinforces AroCell’s opportunities in the US market

    • New Publication from AroCell AB Demonstrating the Value of Thymidine Kinase 1 as a Tumor Biomarker

    • Interim Report Q1 2018

    • AroCell announces license agreement with Roche

    • AroCell TK 210 ELISA presented at LabRoots Drug Discovery Virtual Congress February 21-22, 2018

  • 2017
    • AroCell AB (publ) signs Letter of Intent with Korean-based company, Green Cross Cell Corporation.

    • AroCell AB (publ) Interim Report, Q3 2017

    • Webinar recording is now available

    • Abstract published presenting AroCell TK 210 ELISA from the PROMIX study at the European Society for Medical Oncology Congress in Singapore, November 17-19, 2017

    • AroCell poster presentations at 2017 NCRI Cancer Conference

    • AroCell AB: announces that a distribution agreement has been signed with Pathway Diagnostics Ltd, for distribution of the AroCell TK 210 ELISA test in United Kingdom and Ireland.

    • AroCell Research Poster on TK1 / TK 210 ELISA in Prostate Cancer has been accepted for presentation at the UK National Cancer Research Institute (NCRI) Annual Meeting November 2017

    • AroCell TK 210 ELISA abstract on in-vitro studies of cancer drugs has been accepted for presentation at the National Cancer Research Institute (NCRI) UK symposium

    • Webinar announcement and invitation

    • New application for AroCell TK 210 ELISA opens new opportunities for drug development research

    • AroCell AB Interim Report, Q2 2017

    • TK 210 ELISA appears in latest issue Genetic Engineering & Biotechnology News

    • AroCell AB (publ) Interim report for period 1 January – 31 March 2017

    • AroCell Presentation at 13th Annual Biomarkers & Immuno-Oncology World Congress 2017 in Philadelphia

    • AroCell TK 210 ELISA Webinar Recording is now available!

    • AroCell AB (publ) Year-End Report

    • AroCell research poster on prostate cancer has been accepted by American Association for Cancer Research (AARC)

    • Nomination committee appointed for Annual General Meeting 2017

  • 2016
    • Announcement – AroCell AB PR and Marketing Communications Manager

    • Interim report January – September 2016

    • Ann Hammarstrand appointed as new CFO to AroCell

    • AroCell signs distribution agreement with Eagle Biosciences in the United States

    • New TK 210 ELISA product presentation

    • Oral presentation today of TK 210 ELISA abstract at ISOBM, Chicago

    • Interim report January – June 2016

    • Improved measurement of Thymidine Kinase 1 within the normal range due to improved composition of the zero calibrator.

    • Nasdaq News Release

    • AroCell is approved for listing on the Nasdaq First North and publishes Corporate description

    • AroCell applying for listing on the Nasdaq First North exchange

    • Christine Tadgell new board member in AroCell

    • CEO Jan Stålemark’s presentation at the AGM 2016

    • Report from the Annual General Meeting of AroCell

    • AroCell Newsletter for May is now available

    • Interim report January – March 2016

    • Leading profile in biomarkers joins the AroCell management team

    • New patent strengthens the AroCell patent portfolio

    • Annual Report 2015

    • New clinical study with promising results for the TK 210 ELISA test from AroCell

    • Final call for trading with BTA

  • 2015
    • Nomination committee appointed for Annual General Meeting 2016

    • Oversubscription of preferential rights issue

    • Sign up for our Newsletter!

    • Presentation by CEO Jan Stålemark at Redeye Investor Forum, December 1

    • Interview with CEO Jan Stålemark for Analysguiden, November 2015

    • Presentation from Stora Aktiedagen Göteborg, November 23

    • AroCell announces prospectus, teaser and application form

    • Progress for development of prostate treatment, results from STHLM3 presented today

    • AroCell announces interim report three will be brought forward

    • Announcement of fully guaranteed preferential rights issue of approximately 52.2 MSEK

    • Continued expansion to AroCell organization

    • AroCell presents a robust TK1 blood-test at an international biomarker meeting

    • Clarification regarding press release about CE marking

    • AroCell announces that it has filed for the CE-mark registration of TK 210 ELISA

    • AroCell announces achievement of critical milestone: successful phase 1 review of TK 210 ELISA production process.

    • AroCell recognized by EU Commission and Horizon 2020 Program Committee

    • AroCell strengthens the organization

    • Report from the annual general meeting of AroCell

    • Notice of annual general meeting of AroCell AB (publ)

    • Schedule revision providing for CE-mark during third quarter 2015

    • Revised schedule means CE-marking during the third quarter of 2015

  • 2014
    • New clinical study with promising results

Subscription for news and press releases

  • about
    • A word from the CEO
    • Vision and mission
    • Strategy and goals
    • Board of Directors
    • Management
    • Partnership
    • Company history
    • Policies
  • product
    • AroCell TK 210 ELISA
    • Why measure Thymidine Kinase 1?
    • Performance and technical specifications
    • Instructions for use
  • applications
    • Drug discovery and development
    • Clinical cancer research
      • Hematological malignancies
      • Breast cancer
      • Other solid tumors
    • Clinical studies
    • Scientific references
    • Posters and presentations
  • technologies
    • Thymidine Kinase 1
    • Patent portfolio
    • Scientific references
    • Posters and presentations
  • news & media
    • News
    • Press releases
    • Events
  • investors
    • AroCell – Company overview
    • The share
      • Ownership structure
      • Insider trading
    • Financial report
    • Mergers & Acquisitions
    • Analyst coverage
    • Share issues
      • New share issue 2022
      • NEW SHARE ISSUE 2021
      • New share issue 2019
      • Nyemission 2018
      • Listing at First North 2016
      • Nyemission 2015
    • Press releases
    • Financial presentations
    • Financial calendar
    • General Meeting
      • Extraordinary General Meeting 2022
      • Extraordinary General Meeting 2021
    • Annual General Meeting
      • Annual General Meeting 2022
      • Annual General Meeting 2021
      • Annual General Meeting 2020
      • Annual General Meeting 2019
      • Annual General Meeting 2018
      • Annual general meeting 2017
      • Annual general meeting 2016
      • Annual general meeting 2015
    • Governance
      • Board of Directors
      • Management
      • Articles of association
      • Nomination committee
    • Certified advisor
    • Investor relations contact
  • contact & order
    • Contact
    • Distributors
    • Service
    • Order
    • Q & A
  • English
  • Svenska
AroCell AB Karlsbodavägen 39 168 67 Bromma Stockholm Sweden
  • info@arocell.com
  • +46 (0)18 50 30 20

POLICIES

All of the information appearing on this website is not intended to be used for medical diagnosis or treatment. Information provided on this website does not either constitute medical and/or other professional advice. AroCell TK 210 ELISA is CE-marked and registered by the Swedish Medical Products Agency.

We use cookies to improve the user experience and gather anonymous visitor statistics. By using our website, you agree to the use of cookies.

I agree.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of the cookies.
SettingsAccept
Manage consent

Overview

Cookies are a file that is sent from our server and stored in your browser. We use cookies to improve the user experience and to collect anonymous visitor statistics. You can control the use of cookies via settings in your browser, but keep in mind that some services may not work as expected if you block or delete cookies.
Necessary Cookies
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
SAVE & ACCEPT